Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia
BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has…